Publications and 
announcements

We have the immense pleasure and honor to announce that Adrien Picod received on the 18th of December the Albert Sézary Prize from the ACADEMIE NATIONALE DE MEDECINE DE FRANCE for his research on the role of circulating dipeptidyl peptidase 3 (DPP3) in circulatory failure. The work has been conducted in collaboration with researchers from many institutions in Europe and 4TEEN4: Alexandre Mebazaa, Azibani Feriel, Stéphane Gaudry, Bruno Garcia, Francesca Manicone, Antoine Herpain, Fabio Silvio Taccone, Karine Bourgeois, Andreas Bergmann. Watch here the video of the Award ceremony.

The First Closing of our Series C financing round was notarized yesterday with 14m EUR. We thank our investors for their continued support and interest in our program which is unique and has the potential to save many patients. We warmly welcome Görlich GmbH & Co. 1. Biotech KG as the 10m EUR lead investor of this First Closing. CEO Andreas Bergmann says: “This is an important step in our journey towards developing our drug and making it accessible to patients in need. I would like to thank our team for the great achievements we recently made.”

This month, Florian A. Wenzl, MD, of the Center for Molecular Cardiology at the University of Zurich, Switzerland, earned a European Society of Cardiology (ESC) Young Investigator Award (YIA) in Clinical Science. The YIA-winning study, ‘Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes’,3 identifies circulating dipeptidyl peptidase 3 (cDPP3) as a novel biomarker of cardiogenic shock and increased mortality in patients with ACS.        

Today, 4TEEN4 Pharmaceuticals announces dosing of the first subject in Phase 1 study, a single -center, randomized, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of Procizumab. Phase I study is being conducted at Radboud University, Nijmagen NL, under the supervision of Prof. Peter Pickkers. The commencement of Phase I clinical trial represents the culmination of extensive preclinical research and rigorous safety evaluations.

4TEEN4 Pharmaceuticals was awarded a 150,000 € DATIpilot grant from German Bundesministerium für Bildung und Forschung for a  SURVIVE "Schnelle und zuverlässige Diagnose des kardiogenen und septischen Schocks mittels DPP3-Bluttest in der Akut- und Notfallmedizin" project.  

4TEEN4 Pharmaceuticals and Boditec Med are pleased to announce signing of an out licensing agreement for the use of 4TEEN4 owned DPP3 biomarker on Boditech’s proprietary Afias and ichroma™ platforms. Boditec will develop DPP3 for the prediction and monitoring of cardiogenic shock in patients with acute coronary syndrome and acute heart failure. In addition Boditech became a shareholder of 4TEEN4 Pharmaceuticals by acquiring 3.03% stake in the company.